How this company measures up on the fundamentals that matter
STERIS plc provides infection prevention products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in procedure rooms, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument, devices, and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The AST segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of contract sterilization and laboratory facilities, as well as integrated sterilization equipment and control systems to medical device manufacturers and research institutions. The Life Sciences segment designs, manufactures, and sells consumable products, such as pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. It serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is headquartered in Mentor, Ohio.
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Trading at $213, 47% above fair value of $145. Moderate competitive position. Passes all ethical screens. Ranks better than 59% of screened stocks.
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Trading characteristics and market positioning
Balance sheet strength and cash generation — the foundation of long-term value
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-05 | FELDMANN CYNTHIA L | Director | 3,098 | $734,877 | |
| 2026-03-05 | FELDMANN CYNTHIA L | Director | 3,098 | $471,887 | |
| 2026-01-02 | MCGOWAN LINDSEY | Officer | 798 | — | |
| 2025-11-21 | MADSEN JULIA | Officer | 5,008 | $1,312,096 | |
| 2025-11-21 | MADSEN JULIA | Officer | 5,008 | $642,139 | |
| 2025-11-18 | TAMARO RENATO | Officer and Treasurer | 5,036 | $1,297,040 | |
| 2025-11-18 | TAMARO RENATO | Officer and Treasurer | 3,536 | $644,330 | |
| 2025-11-11 | ZANGERLE JOHN ADAM | General Counsel | 15,000 | $3,977,100 | |
| 2025-11-11 | ZANGERLE JOHN ADAM | General Counsel | 15,000 | $1,045,800 | |
| 2025-10-06 | CARESTIO DANIEL A | Chief Executive Officer | 159 | $38,449 |
Congressional trading disclosures involving this instrument
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-04-24 | Ro Khanna | Democrat | Purchase | 15K–50K |
| 2026-04-14 | Scott Peters | Democrat | Purchase | 50K–100K |
| 2026-04-13 | Ro Khanna | Democrat | Purchase | 15K–50K |
| 2026-04-13 | Ro Khanna | Democrat | Purchase | 15K–50K |
| 2026-04-13 | Ro Khanna | Democrat | Purchase | 1K–15K |
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15